MELA Sciences Inc  

(Public, NASDAQ:MELA)   Watch this stock  
Find more results for MELA
0.550
+0.037 (7.11%)
Real-time:   9:30AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.55 - 0.55
52 week 0.51 - 1.39
Open 0.55
Vol / Avg. 0.00/556,455.00
Mkt cap 26.27M
P/E     -
Div/yield     -
EPS -0.61
Shares 47.76M
Beta 0.56
Inst. own 19%
May 15, 2014
MELA Sciences Annual Shareholder Meeting - 9:00AM EDT - Add to calendar
May 5, 2014
Q1 2014 MELA Sciences Earnings Release (Estimated) Add to calendar
Mar 17, 2014
Q4 2013 MELA Sciences Earnings Conference Call - Webcast
Mar 17, 2014
Q4 2013 MELA Sciences Earnings Release
Feb 6, 2014
MELA Sciences at SeeThruEquity Winter Microcap Investor Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -3297.95% -4841.05%
Operating margin -3154.60% -4502.61%
EBITD margin - -3840.30%
Return on average assets -135.56% -165.26%
Return on average equity -198.99% -233.02%
Employees 45 -
CDP Score - -

Address

Suite 1, 50 South Buckhout St.
IRVINGTON, NY 10533
United States - Map
+1-914-5913783 (Phone)
+1-914-5913785 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

MELA Sciences, Inc. is a medical device company focused on the commercialization of its product, MelaFind, and the further design and development of MelaFind and its technology. MelaFind is a non-invasive, point-of-care (in the doctor's office) instrument to aid in the detection of melanoma. MelaFind, features a hand-held component that emits light of multiple wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing classification algorithms, trained on the Company's database of melanomas and benign lesions, to provide information to assist in the management of the patient's disease, including information useful in the decision whether to biopsy the lesion.

Officers and directors

Robert C. Coradini Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Rosemary A. Crane President, Chief Executive Officer, Treasurer, Secretary, Director
Age: 54
Bio & Compensation  - Reuters
Robert W. Cook Principal Financial Officer, Treasurer, Secretary
Age: 58
Bio & Compensation  - Reuters
Tony Dimun Director
Bio & Compensation  - Reuters
Jeffrey F. O'Donnell Sr. Director
Age: 47
Bio & Compensation  - Reuters
David K. Stone Director
Age: 56
Bio & Compensation  - Reuters
Kathryn B. Swintek Director
Age: 60
Bio & Compensation  - Reuters
LuAnn Via Director
Age: 59
Bio & Compensation  - Reuters